CTKB

CYTEK BIOSCIENCES INC

Healthcare | Small Cap

-$0.10

EPS Forecast

$45.16

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-08-29

Cytek Biosciences (CTKB) Q2 2026: instrument momentum, recurring revenue grows, and the long road to profitability

Executive snapshot: CTKB reports Q2 2026 results with revenue growth and stronger recurring revenues, but a still-negative bottom line

Cytek Biosciences Inc. (Nasdaq: CTKB) reported second-quarter 2026 results that underscore a company well-positioned on instrument adoption and an expanding service-revenue stream, even as earnings per share (EPS) remain negative for the period. The company posted revenue of $48.1 million, up 6% from the year-ago quarter, with GAAP gross profit of $28.3 million and a gross margin of 59%. On an adjusted basis, gross margin was 61%. The quarterly net loss came in at $12.2 million, with operating losses of $11.4 million and an adjusted EBITDA loss of $1.5 million. These numbers imply a negative EPS for the quarter, though the filing does not provide a per-share figure.

Cytek updated its revenue forecast for 2026, guiding full-year revenue to $207–$212 million, lifting the midpoint by $1 million versus prior guidance. The company notes ongoing instrumentation demand in the U.S. and China, aided by expanding recurring revenue from service and reagents, which reached $18.5 million in Q2 and represented 35% of trailing-12-month revenue, up from 32% a year earlier.

Key highlights and what they portend

  • Product momentum: Cytek launched Borealis, a 7-laser full spectrum cytometer capable of 60-color panels, and introduced Aurora Evo configurations with expanded automation to suit highly automated labs. These product moves underpin the instrument growth story highlighted by the company.
  • Recurring revenue expansion: 35% of trailing-12-month revenue is now recurring, up from 32% year-over-year. That shift is meaningful for long-term revenue visibility even as optics-and-demand cycles play out in instrument categories.
  • Installed base and utilization: Total installed Cytek instruments reached 3,933, adding 142 units in Q2 2026, signaling continued channel momentum and field deployment that could bolster service and reagent revenue over time.
  • Guidance and profitability trajectory: While the top line is rising, operating losses persist, and the company notes litigation-related and personnel costs contributing to higher SG&A. The updated revenue forecast reflects confidence in the mid-term growth path, but the EPS/GAAP profitability question remains unresolved for 2026.

Financials at a glance: margins, expenses, and cash runway

Gross margin improvements are notable: GAAP gross margin rose to 59% in Q2 2026 from 52% a year earlier, with adjusted gross margin at 61%. Excluding a one-time tariff refund, GAAP and adjusted gross margins would have been 53% and 56%, respectively—an important reminder that one-off items can distort quarterly margin reads.

Operating expenses rose 15% year over year to $39.7 million, driven by increases in research and development, sales and marketing, and G&A. The quarterly loss from operations was $11.4 million, and net loss totaled $12.2 million. On the liquidity side, Cytek held $262.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026, essentially flat versus March 31, 2026.

Guidance and strategic context

The company reaffirmed its 2026 revenue forecast of $207–$212 million, with the midpoint nudged higher by about $1 million. Management framed the results in the context of accelerating instrument adoption, expanding recurring revenue, and ongoing investments in products, people, and operations that they believe will pay off in the remainder of 2026 and beyond.

Cytek emphasized that instrument growth is strongest in the U.S. and China, which may influence competitive dynamics in the global flow cytometry market. The emphasis on automation and expanded reagent ecosystems suggests a longer-term strategy aimed at sticky, recurring revenue streams that could help offset the ups and downs of quarterly instrument shipments.

Voices from the conference room

“Our second-quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instruments in the U.S. and in China and ongoing and consistent expansion of our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Looking ahead, our priorities remain clear: accelerating adoption of our instrument platforms, including newly launched instruments, expanding recurring revenue business and extending our technology leadership. We believe our investments in products, people, and operations position Cytek well for the remainder of 2026 and the long-term opportunity ahead.”

Implications for peers and the sector

Cytek’s mix shift toward recurring revenue mirrors a broader investor preference for durable, service-forward models in instrument-intensive sectors. The Borealis and Aurora Evo launches reflect a competitive stance aimed at speed, automation, and high-parameter performance—features that matter as labs chase throughput and data richness. If Cytek can convert instrument utilization into a meaningful and growing service and reagent business, the sector could see more emphasis on lifecycle economics rather than one-off hardware cycles. For peers, the quarter reinforces the importance of product ecosystems and automation capabilities as differentiators in a crowded market.

Risks and what to watch

Profitability remains a focal point. With net losses and a sizable SG&A base, investors will parse how quickly Cytek can translate instrument adoption into sustained gross margins, lower unit costs, and a path to positive EBITDA. The cadence of revenue growth, especially from recurring streams, will be critical to the stock’s valuation narrative (and to any EPS consensus adjustments or earnings surprise observations should consensus estimates be issued in future quarters).

Bottom line

Cytek’s Q2 2026 story is a reminder that growth in high-tech lab hardware can outpace near-term profitability. Revenue growth and a rising share of recurring revenue provide a foundation for longer-term cash generation, but the market will want to see a path to sustainable profitability. The CTKB machine-learning of instrument configurations, automation, and reagent ecosystems reads like a deliberate strategy to deepen lab workflows, reduce manual bottlenecks, and potentially lift the lifetime value of a customer. If Cytek can translate pipeline momentum into consistent earnings leverage, the next few quarters could bring a more confident narrative for both investors and sector peers.